These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 9003517

  • 1. Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase.
    Leonard DM, Shuler KR, Poulter CJ, Eaton SR, Sawyer TK, Hodges JC, Su TZ, Scholten JD, Gowan RC, Sebolt-Leopold JS, Doherty AM.
    J Med Chem; 1997 Jan 17; 40(2):192-200. PubMed ID: 9003517
    [Abstract] [Full Text] [Related]

  • 2. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors.
    Qian Y, Vogt A, Sebti SM, Hamilton AD.
    J Med Chem; 1996 Jan 05; 39(1):217-23. PubMed ID: 8568811
    [Abstract] [Full Text] [Related]

  • 3. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J, Kung HF, Manne V.
    Cell Mol Biol Res; 1994 Jan 05; 40(4):313-21. PubMed ID: 7866432
    [Abstract] [Full Text] [Related]

  • 4. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.
    J Med Chem; 1996 Jan 05; 39(1):224-36. PubMed ID: 8568812
    [Abstract] [Full Text] [Related]

  • 5. [Anti tumor activity of farnesyl transferase inhibitor].
    Yoshimatsu K, Nagasu T.
    Gan To Kagaku Ryoho; 1997 Jan 05; 24(2):145-55. PubMed ID: 9030225
    [Abstract] [Full Text] [Related]

  • 6. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC, Watkins JD, Ferguson SB, Foley LH, Georgopapadakou NH.
    Biochem Biophys Res Commun; 1995 Dec 26; 217(3):728-32. PubMed ID: 8554591
    [Abstract] [Full Text] [Related]

  • 7. Farnesyltransferase as a target for anticancer drug design.
    Qian Y, Sebti SM, Hamilton AD.
    Biopolymers; 1997 Dec 26; 43(1):25-41. PubMed ID: 9174410
    [Abstract] [Full Text] [Related]

  • 8. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
    Nara S, Tanaka R, Eishima J, Hara M, Takahashi Y, Otaki S, Foglesong RJ, Hughes PF, Turkington S, Kanda Y.
    J Med Chem; 2003 Jun 05; 46(12):2467-73. PubMed ID: 12773050
    [Abstract] [Full Text] [Related]

  • 9. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing.
    Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM.
    J Biol Chem; 1995 Jan 13; 270(2):660-4. PubMed ID: 7822292
    [Abstract] [Full Text] [Related]

  • 10. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA, Sigman CC.
    Cancer Epidemiol Biomarkers Prev; 1997 Apr 13; 6(4):267-82. PubMed ID: 9107432
    [Abstract] [Full Text] [Related]

  • 11. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB, Silverman KC, Jayasuriya H, Kim BM, Amo SE, Wilson FR, Rew DJ, Schaber MD, Bergstrom JD, Koblan KS, Graham SL, Kohl NE, Gibbs JB, Singh SB.
    J Med Chem; 1998 Nov 05; 41(23):4492-501. PubMed ID: 9804689
    [Abstract] [Full Text] [Related]

  • 12. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep 05; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 13. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ, Guitton JD, Baudoin B, Lelièvre Y, Duchesne M, Parker F, Fromage N, Commerçon A.
    J Med Chem; 1997 Jun 06; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
    Chen X, Hasuma T, Yano Y, Yoshimata T, Morishima Y, Wang Y, Otani S.
    Anticancer Res; 1997 Jun 06; 17(4A):2555-64. PubMed ID: 9252680
    [Abstract] [Full Text] [Related]

  • 15. N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase.
    deSolms SJ, Giuliani EA, Graham SL, Koblan KS, Kohl NE, Mosser SD, Oliff AI, Pompliano DL, Rands E, Scholz TH, Wiscount CM, Gibbs JB, Smith RL.
    J Med Chem; 1998 Jul 02; 41(14):2651-6. PubMed ID: 9651171
    [Abstract] [Full Text] [Related]

  • 16. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 17. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase.
    Roskoski R, Ritchie P.
    Arch Biochem Biophys; 1998 Aug 15; 356(2):167-76. PubMed ID: 9705207
    [Abstract] [Full Text] [Related]

  • 18. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.
    Qian Y, Blaskovich MA, Saleem M, Seong CM, Wathen SP, Hamilton AD, Sebti SM.
    J Biol Chem; 1994 Apr 29; 269(17):12410-3. PubMed ID: 8175645
    [Abstract] [Full Text] [Related]

  • 19. Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate.
    Long SB, Casey PJ, Beese LS.
    Biochemistry; 1998 Jul 07; 37(27):9612-8. PubMed ID: 9657673
    [Abstract] [Full Text] [Related]

  • 20. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A, Bergemann S, Gust R, Sattler I, Schlitzer M.
    Arch Pharm (Weinheim); 2003 Jul 07; 336(4-5):242-50. PubMed ID: 12916059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.